Privilège Ventures
VC Fund
Zürich, Switzerland
Privilège Ventures is a Swiss-based Venture Capital firm, authorized by the Swiss Financial Market Supervisory Authority (FINMA, www.finma.ch) as venture capital asset manager, investing in promising early-stage startups. Headquartered in Lugano and with offices in Zurich and Boston, we aim to support young founders on a mission to build thefuture. Our unique values derive from previous experiences as founders, entrepreneurs, operators and investors. We provide unceasing support, expertise, and valuable network access to help entrepreneurs forge ahead.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 54%
Last updated:
For AI agents: llms.txt
Industries Privilège Ventures invests in
Stages Privilège Ventures invests in
Countries Privilège Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $1.2M–$5.9M
- Pre-Seed
- $667k–$1.6M
- Series A
- $4.1M–$7M
Investment Focus
Industry
- Health Care 6 (25%)
- Software 5 (21%)
- Wearables 3 (13%)
- Biotechnology 3 (13%)
- Health Diagnostics 3 (13%)
Stage
- Seed 11 (46%)
- Pre-Seed 3 (13%)
- Series A 3 (13%)
- Funding Round 2 (8%)
- Venture - Series Unknown 1 (4%)
Country
- Switzerland 15 (63%)
- Italy 1 (4%)
- France 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cesare Pezzini
Associate; Associate
|
Associate; Associate | Total investments: 1 | Find email | |
Mershad Javan
Venture Partner
|
Venture Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Xsensio
|
Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developedat the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring. | $7M / Series A / Mar 02, 2026 | |
ENANTIOS
|
ENANTIOS specializes in creating benchtop analytical instruments that provide industries, research institutions, and academic facilities. | $2M / Seed / Jun 27, 2024 | |
Develop Players
|
Develop-Players is a spin-off of the University of Bologna that develops scientifically validated videogames for the neuropsychological screening, assessment, and cognitive training of children and adolescents with Specific Learning Disorders and ADHD. Combining psychometrics, software development, and game design, the company creates engagingtools that help clinicians and families identify cognitive strengths and weaknesses, support early diagnosis, and enhance cognitive functions through playful, evidence-based experiences. | $666.5K / Pre-Seed / Dec 27, 2023 | |
|
Xsensio
|
Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developedat the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring. | $5.9M / Seed / Dec 17, 2022 | |
|
Xsensio
|
Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developedat the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring. | $5.9M / Seed / Dec 17, 2022 | |
TYXIT
|
TYXIT is linking musicians wirelessly without configuration, allowing a personal audio monitoring. | $2M / Seed / Oct 25, 2022 | |
|
TYXIT
|
TYXIT is linking musicians wirelessly without configuration, allowing a personal audio monitoring. | $2M / Seed / Oct 25, 2022 | |
|
TYXIT
|
TYXIT is linking musicians wirelessly without configuration, allowing a personal audio monitoring. | $2M / Seed / Oct 25, 2022 | |
Avelo
|
Avelo mission is to save lives by bringing fast and actionable infectious disease diagnoses to primary care. | $2.3M / Seed / Sep 20, 2022 | |
Wyth
|
Wyth creates private digital spaces for virtual and hybrid audiences. With our fully customizable platform organizations can build a seamless experience and an online home for their communities to connect, learn, work, share and play without ever leaving Wyth. We give our customers full control over their brand experience, data ownership andbusiness relationships. | $1.6M / Pre-Seed / Jul 15, 2022 | |
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Privilège Ventures invest in?
Privilège Ventures invests primarily in Health Care, Software and Wearables startups, most often at Seed and Pre-Seed stage. Most of the 24 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Privilège Ventures's check size?
Privilège Ventures typically joins rounds of $1.2M–$5.9M at Seed, $667k–$1.6M at Pre-Seed and $4.1M–$7M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Privilège Ventures participates in.
How do I contact Privilège Ventures?
Public channels for Privilège Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Privilège Ventures?
The team at Privilège Ventures includes Cesare Pezzini (Associate; Associate) and Mershad Javan (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
